Home parenteral antibiotic therapy is gaining increasing acceptance in the medical community. Shortened hospitalization, improved hospital bed turnover, earlier resumption of the patient's normal daily activities, alleviation of emotional stress experienced by both the patient and the family during an ongoing hospital stay, and financial incentives are the major benefits (1, 2, 4, (7) (8) (9) 11) .
Ceftriaxone is a broad-spectrum cephalosporin with pharmacokinetic and antimicrobial characteristics that make it a good candidate for outpatient parenteral therapy (6) . It has a spectrum of activity which includes most of the grampositive and gram-negative organisms associated with infections that are feasible to treat with home parenteral antibiotics. Its prolonged half life of 6 to 8 h allows for once-a-day dosing which still produces therapeutic levels in serum. This convenient dosing schedule facilitates acceptance of treatment by patients, maximizes their free time, and minimizes the burden of the health care provider.
Ceftriaxone can be given intravenously (i.v.) or intramuscularly (i.m.) with equivalent antibiotic levels in serum. When ceftriaxone is reconstituted with lidocaine, i.m. administration is virtually painless, which enhances patient acceptance.
Patients were accepted for study if they had a serious but stable bacterial infection that required further parenteral antibiotic therapy which could be administered in a home program. Antibiotics other than ceftriaxone could be received as part of their initial therapy in the hospital, but ceftriaxone was the only antibiotic administered at home. Causative organisms were required to be susceptible to ceftriaxone, as determined by tube dilution or agar diffusion methods: for a susceptible organism, the MIC was <16 ,ug/ ml. Exclusions included patients with known or suspected hypersensitivity to 3-lactam antibiotics, pregnant or nursing women, and patients with bacterial meningitis.
Study nurses visited the homes or workplaces of the patients to administer ceftriaxone, given as either a 1-or 2-g dose by the i.m. route every 24 h. A 1-g vial of ceftriaxone was reconstituted with 3.6 ml of 1% lidocaine without epinephrine, resulting in a total volume of 4 ml. A maximum of 2 ml was given per i.m. injection; therefore, two and four injections were necessary for 1-and 2-g doses, respectively. The gluteus and lateral thigh were the primary sites for i.m. injection.
Treatment outcomes were designated as cures, improve- Total antimicrobial therapy, including inpatient and home treatment, lasted for an average of 33 days (range, 14 to 51 days), and ceftriaxone comprised 75% of the total treatment courses. Home therapy consisted of ceftriaxone alone, and it was given for an average course of 19 days (range, 4 to 33 days).
Osteomyelitis, an infection often suitable for outpatient therapy, accounted for 16 of the 31 cases (Table 1 ). All cases were confirmed by bone biopsy. These patients underwent, when indicated, aggressive debridement of infected soft tissue and bone, and hardware was removed in all cases except one. The etiologies included contiguous spread from infected adjacent soft tissue (two patients), trauma (five patients), implantation of prosthetic devices (five patients), and hematogenous spread (four adults and one child). The follow-up for the cases of osteomyelitis designated as cures ranged from 2 to 14 months.
All seven bacteremic infections were successfully treated, including two cases of Streptococcus viridans endocarditis and two cases of Staphylococcus aureus endocarditis.
The only treatment failure was a case of external otitis with mastoiditis initially caused by S. aureus. The patient initially responded to ceftriaxone therapy but relapsed shortly after stopping the drug, and Pseudomonas aeruginosa was isolated from the site.
Twenty-five patients were treated with a single 1-g dose of ceftriaxone per day. Six patients (five with osteomyelitis and one with endocarditis) received 2 g daily for the initial portion of their course and completed the final half to two-thirds of the course with the 1-g dose.
The infecting organisms and their MICs of ceftriaxone are shown in Table 2 . S. aureus was the major pathogen, isolated in 19 patients. Nonenterococcal streptococci, Propionibacterium acnes, Bacteroides fragilis, and nonpseudomonal gram-negative rods were the other microorganisms.
i.m. therapy was well tolerated. Local pain after an i.m. injection was an uncommon complaint. There were no cases of sterile abscesses resulting from i.m. injection. None of the 31 patients requested a change to i.v. administration, an available option.
Four of the thirty-one patients had adverse reactions which may have been related to ceftriaxone, none of which led to cessation of therapy. These reactions, each of which ANTIMICROB. AGENTS CHEMOTHER. was experienced by one patient, included low leukocyte count, abnormal liver function tests, rash, and possible drug fever.
Home parenteral antibiotic therapy is increasingly used in our health care system. The efficacy of this form of therapy was demonstrated previously (1, 3, 7-9, 11), and our study, using ceftriaxone, confirmed these findings. The unique aspect of this trial was the demonstration of the effective use of i.m. ceftriaxone in outpatient antibiotic therapy. In previous studies of which we are aware, home antibiotics were administered by the i.v. route.
Twenty-five patients received a daily dose of 1 g of ceftriaxone, and the other six patients started with 2 g but were switched later to the 1-g dose. Although an occasional situation may arise when 2 g/day may prove to be more suitable, 1 g should be efficacious for most patients. i.m. injections were well tolerated. We believe two factors are responsible for this favorable result. The importance of reconstituting ceftriaxone with 1% lidocaine for use in i.m. injections needs to be emphasized. This ploy allowed for comfortable administration, which was accepted even by initially skeptical patients. In addition, 2 ml was the maximum volume administered. Although this required two and four injections, respectively, for the 1-and 2-g doses, we believe this approach minimizes discomfort. In this experience, local pain or symptoms after i.m. injection was a rare occurrence.
The i.m. route of administration can be more convenient for both the patient and the health care provider. The drug can be administered by minimally trained individuals, thereby increasing situations in which home therapy becomes feasible. Fears that some patients may harbor of an indwelling i.v. line or the need for frequent i.v. replacement can be alleviated with an i.m. approach. It also circumvents the problem of difficult i.v. access, a common situation with chronically ill patients, especially towards the end of a prolonged course of therapy. The potential complications of phlebitis and line-associated superinfection are also avoided (5, 10) .
Ceftriaxone appears to be a good antimicrobial agent for use in home parenteral therapy. Its administration via the i.m. route when reconstituted with lidocaine appears to be well tolerated and is an alternative to the i.v. route in home therapy.
